These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7565235)

  • 1. The Tay-Sachs disease prevention program in Australia: Sydney pilot study.
    Burnett L; Proos AL; Chesher D; Howell VM; Longo L; Tedeschi V; Yang VA; Siafakas N; Turner G
    Med J Aust; 1995 Sep; 163(6):298-300. PubMed ID: 7565235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
    Rozenberg R; Pereira Lda V
    Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for carriers of Tay-Sachs disease in the ultraorthodox Ashkenazi Jewish community in Israel.
    Broide E; Zeigler M; Eckstein J; Bach G
    Am J Med Genet; 1993 Aug; 47(2):213-5. PubMed ID: 8213907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
    Kronn D; Jansen V; Ostrer H
    Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests.
    Triggs-Raine BL; Feigenbaum AS; Natowicz M; Skomorowski MA; Schuster SM; Clarke JT; Mahuran DJ; Kolodny EH; Gravel RA
    N Engl J Med; 1990 Jul; 323(1):6-12. PubMed ID: 2355960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews.
    Lew RM; Proos AL; Burnett L; Delatycki M; Bankier A; Fietz MJ
    Med J Aust; 2012 Dec; 197(11):652-4. PubMed ID: 23230938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mutations and DNA-based screening in non-Jewish carriers of Tay-Sachs disease.
    Akerman BR; Natowicz MR; Kaback MM; Loyer M; Campeau E; Gravel RA
    Am J Hum Genet; 1997 May; 60(5):1099-106. PubMed ID: 9150157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tay-Sachs disease and HEXA mutations among Moroccan Jews.
    Kaufman M; Grinshpun-Cohen J; Karpati M; Peleg L; Goldman B; Akstein E; Adam A; Navon R
    Hum Mutat; 1997; 10(4):295-300. PubMed ID: 9338583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group.
    Myerowitz R
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3955-9. PubMed ID: 3375249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation in the HEXA gene specific to Tay-Sachs disease carriers of Jewish Iraqi origin.
    Karpati M; Peleg L; Gazit E; Akstein E; Goldman B
    Clin Genet; 2000 May; 57(5):398-400. PubMed ID: 10852376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin.
    Petersen GM; Rotter JI; Cantor RM; Field LL; Greenwald S; Lim JS; Roy C; Schoenfeld V; Lowden JA; Kaback MM
    Am J Hum Genet; 1983 Nov; 35(6):1258-69. PubMed ID: 6650504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of enzyme and DNA analysis in a Tay-Sachs disease carrier screening program.
    Yoo HW; Astrin KH; Desnick RJ
    J Korean Med Sci; 1993 Feb; 8(1):84-91. PubMed ID: 8343225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of the Tay-Sachs disease splice and insertion mutations in the UK Ashkenazi Jewish population.
    Landels EC; Ellis IH; Fensom AH; Green PM; Bobrow M
    J Med Genet; 1991 Mar; 28(3):177-80. PubMed ID: 1828838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carrier screening panels for Ashkenazi Jews: is more better?
    Leib JR; Gollust SE; Hull SC; Wilfond BS
    Genet Med; 2005 Mar; 7(3):185-90. PubMed ID: 15775754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tay-Sachs disease screening program in the U.S. as a model for the control of genetic disease: an historical view.
    Edelson PJ
    Health Matrix Clevel; 1997; 7(1):125-33. PubMed ID: 10167171
    [No Abstract]   [Full Text] [Related]  

  • 18. Tay-Sachs disease screening and counseling families at risk for metabolic disease.
    Sutton VR
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):287-96. PubMed ID: 12108829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for the Tay-Sachs carrier: a compromise program.
    Potter JL; Robinson HB
    Clin Chem; 1981 Apr; 27(4):523-5. PubMed ID: 7471417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tay-Sachs disease in Moroccan Jews: deletion of a phenylalanine in the alpha-subunit of beta-hexosaminidase.
    Navon R; Proia RL
    Am J Hum Genet; 1991 Feb; 48(2):412-9. PubMed ID: 1825014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.